Traders should monitor upcoming mid-2026 clinical readouts for tagmokitug and casdozokitug, which could serve as major catalysts. The improved financial position reduces near-term dilution risk, while LOQTORZI's growth trajectory supports potential revaluation if sales continue accelerating.
CHRS drugs
CHRS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 10 $1.95entry
- T+1 · 8mo ago −8.72%α −8.61% · $1.78
- T+5 · 8mo ago −13.85%α −12.94% · $1.68
- T+20 · 7mo ago −12.82%α −12.67% · $1.70
- T+60 · 6mo ago −24.62%α −36.30% · $1.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Coherus Oncology reported strong revenue growth for LOQTORZI, with full-year 2025 net revenue reaching $42.2 million, up 60% YoY, driven by increasing patient demand and treatment duration. The company significantly reduced its debt by 90% to $38.8 million and bolstered its cash position to $172.1 million through equity financings, while advancing a promising oncology pipeline with multiple 2026 clinical readouts expected.
Key Financial Metrics
Key Facts
- LOQTORZI net revenue grew 60% YoY to $42.2 million in 2025, up from $26.4 million in 2024
- Q4 2025 LOQTORZI revenue was $12.4 million, up 64% YoY and 11% QoQ
- Debt reduced from $480 million peak to $38.8 million by end of 2025
- Cash, cash equivalents, and marketable securities totaled $172.1 million as of December 31, 2025
- Company raised $54.9 million in gross proceeds from two equity offerings in late 2025 and early 2026
- Net loss from continuing operations narrowed to $183.1 million in 2025 from $215.4 million in 2024
- Phase 2 data for casdozokitug in uHCC showed 38% ORR and 17% CR rate; multiple 2026 clinical readouts expected
Financial Impact
Revenue increased by $15.8 million YoY; net loss improved by $32.3 million; cash position increased by $46.1 million despite operating losses
Risk Factors
- High cash burn: $138.5 million used in operating activities in 2025
- Significant dilution from recent equity raises: ~33 million new shares issued in 2025-2026
- Pipeline remains early-stage with no guarantees of clinical success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252311 |
Track record
15 reports on CHRS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
- Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
- Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
- Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
- Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
- May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
- May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers